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Abstract Cytokine and growth-factor ligands typically signal through homo- or hetero-dimeric
cell surface receptors via Janus Kinase (JAK/TYK), or Receptor Tyrosine Kinase (RTK)-mediated
trans-phosphorylation. However, the number of receptor dimer pairings occurring in nature is
limited to those driven by natural ligands encoded within our genome. We have engineered
synthethic cytokines (synthekines) that drive formation of cytokine receptor dimer pairings that are
not formed by endogenous cytokines and that are not found in nature, and which activate distinct
signaling programs. We show that a wide range of non-natural cytokine receptor hetero-dimers are
competent to elicit a signaling output. We engineered synthekine ligands that assembled IL-2Rb/IL-
4Ra or IL-4Ra/IFNAR2 receptor heterodimers, that do not occur naturally, triggering signaling and
functional responses distinct from those activated by the endogenous cytokines IL-2, IL-4, and IFN.
Furthermore, hybrid synthekine ligands that dimerized a JAK/STAT cytokine receptor with a
receptor tyrosine kinase (RTK) also elicited a signaling response. Synthekines represent a new
family of synthetic ligands with pre-defined receptors, but ’orphan’ functions, that enable the full
combinatorial scope of dimeric signaling receptors encoded within the human genome to be
exploited for basic research and drug discovery.
DOI: 10.7554/eLife.22882.001
Introduction
Cytokines and growth factor agonists activate JAK/STAT, or RTK linked homo- or hetero-dimerize
cell surface receptors, respectively, to elicit signaling through intracellular trans-phosphorylation by
receptor-associated kinases. The identity of the specific receptor chains within the dimer determines
the signaling and functional response (Moraga et al., 2014; Stroud and Wells, 2004; Ullrich and
Schlessinger, 1990; Wang et al., 2009; Wells and de Vos, 1993). In the case of cytokines, they act
as bi-specific ligands, and determine which receptors are included in the dimers by binding to each
of the two receptor extracellular domains, thus acting to bridge or cross-link the dimeric signaling
complex. Cytokine receptor dimerization leads to the activation of an intracellular JAK/STAT signal-
ing pathway, comprised of four Janus Kinases (JAK1-3, TYK2) (Ihle et al., 1995; O’Shea and Plenge,
2012) and seven signal transducer and activator of transcription (STAT1-6) proteins (Delgoffe et al.,
2011; Levy and Darnell, 2002; Murray, 2007). While cytokines are specific for the extracellular
domains of their receptors, the JAK/TYK/STAT signaling modules are found in many combinations in
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endogenous cytokine receptor signaling complexes, and thus are capable of extensive cross-talk.
Ligands for Receptor Tyrosine Kinase (RTK) receptors (such as EGF, VEGF, etc.) also initiate signaling
through receptor dimerization, although the molecular mechanisms can be quite distinct from cyto-
kines. In the cases of both JAK/STAT receptors and RTKs, the role of their respective ligands is to
induce a positioning of the receptor subunits into a dimeric orientation and proximity that enables
trans-phosphorylation of both the kinases and the receptor intracellular domains (Lemmon and
Schlessinger, 2010). The sequence requirements (i.e. substrate specificity) of these Tyrosine kinases
can be degenerate to different degrees (Songyang and Cantley, 1995). This offers the possibility
that receptor-associated JAK/TYK and RTK kinases can be redirected, via engineered
extracellular receptor dimerizing ligands, to phosphorylate alternative receptor targets than those
normally driven by the endogenous ligands. Underscoring this possibility, several examples of cross-
talk between JAK/STAT and RTK family receptors have been shown to occur naturally
(Vignais et al., 1996; Grant et al., 2002; Jahn et al., 2007; Wang et al., 2013).
Given that the ligands determine the composition of the receptor subunits comprising
the signaling dimers, and the intracellular JAK/TYK and RTK enzymes are degenerate, the number of
cytokine and growth factor receptor dimer pairings that occur in nature only represents a small pro-
portion of the total number of signaling-competent receptor pairings theoretically allowed by the
system. For example, the human genome encodes for approximately forty different JAK/STAT cyto-
kine receptors. In principle, approximately 1600 unique homo- and hetero-dimeric cytokine receptor
pairs could be generated with the potential to signal through different JAK/TYK/STAT combinations
(Bazan, 1990, 1993; Huising et al., 2006). However, the human genome encodes for less than fifty
different cytokine ligands (Bazan, 1990, 1993; Huising et al., 2006), limiting the scope of cytokine
receptor dimers to those that can be assembled by the natural ligands. A similar argument can be
made for the RTK family of receptors and ligands.
For JAK/STAT cytokine receptors, it has been previously established that genetically modified chi-
meric receptors in which the extracellular domain (ECD) of a cytokine receptor has been fused with
the intracellular domain (ICD) of a different receptor activated signaling in a ligand-dependent man-
ner (Fujiwara et al., 1997; Heller et al., 2012; Kawahara et al., 2006; Ohashi et al., 1994;
Pattyn et al., 1999; Schaeffer et al., 2001). However, for this concept to be practically useful, solu-
ble ligands that co-opt endogenous receptors and assemble non-natural dimers on natural cells and
tissues are required. This could be accomplished by synthetic cytokines, or synthekines, that drive
formation of artificial cytokine receptor pairs not formed by natural endogenous cytokines. Synthe-
kines could potentially activate new signaling programs and elicit unique immunomodulatory activi-
ties compared to genome-encoded cytokines, providing an almost unlimited supply of ligands
to expand the functional scope of cytokine action.
Previous studies have reported the engineering of cytokine variants termed ’fusokines’ that pro-
mote new activities by genetically fusing two intact cytokines via a polypeptide linker, resulting in
dimers of natural receptor signaling dimers (Ng and Galipeau, 2015; Rafei et al., 2009). In this
approach the two connected cytokines each retain activity, so the observed activities of the fused
cytokine are due to both the independent and additive combinations of the two natural cytokine
receptor signaling dimers. The use of engineered ligands (synthekines) that dimerize two different
cytokine receptors in a molecularly defined 1:1 stoichiometry on the surface of responsive cells
presents an alternative approach that leads to unique, rather than additive, signaling outputs.
Formation of a defined dimeric complex, like the one formed by genome-encoded cytokines, allows
precise mechanistic insight into the nature of the signaling complex eliciting the new signaling pro-
grams and activities engaged by these ligands.
To explore the generality of this idea, we expressed and characterized a 10  10 matrix of chime-
ric cytokine receptor pairs using an orthogonal extracellular domain as a common hetero-dimerizing
unit, fused to cytokine receptor intracellular domains, allowing for the evaluation of the signaling of
100 different cytokine receptor dimers. Most cytokine-receptor pairs sampled in this chimeric recep-
tor matrix activated signaling. In a second step, we genetically fused two antagonist versions of IL-2,
IL-4, and interferon (IFN), that form 1:1 receptor-ligand complexes, with a polypeptide linker to engi-
neer synthekines that dimerize non-natural cytokine receptor pairs on the cell surface. Stimulation of
cell lines and peripheral blood mononuclear cells (PBMCs) with engineered synthekines revealed sig-
naling and cellular signatures with features both shared and distinct from the parent cytokines. We
extended the synthekine concept to dimerize c-Kit, a tyrosine kinase receptor for Stem Cell Factor
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(SCF), and thrombopoietin receptor (TpoR), a JAK/STAT cytokine receptor, which resulted in a mea-
surable signaling output that qualitatively differed from that induced by their respective endogenous
ligands. Our results serve as proof of concept that dimerization of non-natural JAK/TYK/STAT and
RTK receptor pairs is a viable approach to generate new signaling programs and activities whose
functional consequences can be explored as if they are newly discovered orphan cytokine ligands,
but with pre-defined receptors.
Results
Signal activation induced by chimeric cytokine receptors
We first wished to determine the potential for JAK/STAT cross-talk between a large number of
enforced non-natural cytokine receptor dimers (Figure 1A). We generated an array of chimeric
receptors, in which the extracellular domains (ECDs) of the IL-1 receptors (IL-1R1 and IL-1R1Acp)
were fused to the transmembrane (TM) and intracellular domains (ICDs) of ten different cytokine
receptors, generating a 10  10 matrix of possible receptor pair combinations (Figure 1B). We used
the IL-1 system for two reasons: (1) IL-1 binds with very high affinity to its receptors, which allows for
signal activation even at low receptor expression levels; and (2) IL-1 does not signal via the canonical
JAK/STAT pathway, eliminating background activity resulting from dimerization of endogenous IL-1
receptors.
Jurkat cells, which express all JAKs and STATs except STAT4, were electroporated with the indi-
cated combinations of chimeric receptors and analyzed for IL-1R1 and IL-1R1Acp surface expression
by flow cytometry (Figure 2—figure supplement 1) and for IL-1-dependent signal activation by
Western blot (Figure 2A and Figure 2—figure supplement 2). Although most IL-1 receptor combi-
nations exhibited robust cell surface expression, very low levels of expression were detected for
some receptor pairs, although signaling by IL-1 stimulation remained detectable (Figure 2—figure
supplements 1–2). Although different receptor combinations activated signaling to different
degrees, binary heat maps depicting phosphorylation of six STATs are presented in Figure 2A. Red
squares indicate signaling, black squares indicate no signaling. As expected, STAT2 and STAT4 were
not activated by any receptor combination due to low STAT2 expression and lack of STAT4 expres-
sion in Jurkat cells (Figure 2A and [Marijanovic et al., 2007]). STAT1 and STAT6 proteins were acti-
vated only by chimeric receptor pairs containing IFNAR2 and IL-4Ra respectively, consistent with the
specific activation of these two STATs by IFNs and the IL-4 and IL-13 cytokines (Figure 2A). In con-
trast, STAT3 and STAT5 proteins were activated by many chimeric receptor pair combinations, con-
sistent with the more pleiotropic use of these two STATs by cytokines (Figure 2A). Although the
majority of receptor pair combinations activated signaling, we also found receptor pairs that did not
induce productive signaling despite robust surface expression (Figure 2—figure supplement 1),
such as IL-2Rb homodimers and IL-13Ra1 homodimers (Figure 2A and Figure 2—figure supple-
ment 2). Overall our data show that most receptor dimer combinations tested activated STAT pro-
teins, revealing the high plasticity of the cytokine-cytokine receptor system.
Signal activation by JAK2/JAK3 cytokine receptor pairs
One striking observation from our chimeric receptor study was that chimeric receptor combinations
pairing JAK2 and JAK3, (i.e. erythropoietin receptor (EpoR)/gc and IL-23R/gc), did not appear to
activate signaling. Interestingly, the JAK2/JAK3 pairing is not found in nature, raising the question of
whether lack of signal activation by this pair could result from structural incompatibilities between
these two kinase molecules that would prevent cross-activation. To test this hypothesis we inserted
alanine residues in the juxtamembrane domain of EpoR, which has been shown to modulate signal-
ing by altering the register of the juxtamembrane region of the receptor (Constantinescu et al.,
2001). Specifically, between one and four alanines were inserted after R251 on the EpoR ICD
(Figure 2B). These EpoR mutants were fused to the IL-1R1 ECD and co-transfected with either IL-
1R1Acp-IFNAR2 (positive control) or IL-1R1Acp-gc in Jurkat cells (Figure 2—figure supplement 3).
Insertion of one, three or four alanines in the juxtamembrane domain of EpoR did not affect its abil-
ity to signal when paired with IFNAR2, but insertion of two alanines, prevented signaling by this
receptor pair (Figure 2C). Insertion of one or three alanines in the juxtamembrane domain of EpoR
did not recover signaling by the EpoR/gc (JAK2/JAK3) receptor pair, insertion of four alanines
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marginally recovered signaling, and insertion of two alanines fully recovered signal activity by this
receptor pair (Figure 2C). These results suggest the existence of structural constraints between
JAK2 and JAK3 limit these two kinases from triggering signaling in our chimeric receptor system.
However, this experiment demonstrates that varying the ligand-receptor geometry in non-natural
receptors pairs using JAK2 and JAK3 is a viable option to recover signaling. Previously we have
Figure 1. Dimerization of non-natural receptor pairs by engineered surrogate ligands. (A) Schematic detailing the
dimerization of new cytokine receptor pairs by synthekines. A hypothetical synthekine recruits receptors A and D
to form a new ternary complex distinct from that formed by each of the cytokines. (B) Schematic representation of
the IL-1-mediated complexation of IL-1R1 and IL-1R1AcP chimeric receptors. The intracellular domains of the
cytokine receptors indicated in the right table were grafted onto the IL-1R1 or IL-1R1AcP extracellular domains.
JAKs and STATs activated by each receptor are indicated in the table.
DOI: 10.7554/eLife.22882.002
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Figure 2. Non-natural cytokine receptor pairs activate signaling. (A) Heatmap representation of STAT molecules activated by the 100 different cytokine
receptor pair combinations generated from the chimeric receptor matrix described in Figure 1B. Results were binary coded to 1, presence of band, or
0, absence of band, in western blot analysis. (B) Schematic representation of the designed IL-1-inducible chimeric receptors (left). Alanine insertion
mutagenesis of the EpoR juxtamembrane domain is detailed in the center. Alanine residues (1A, 2A, 3A, or 4A) were inserted after R251. Alpha-helical
Figure 2 continued on next page
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shown that altering the dimer geometry of EpoR with surrogate ligands results in differential signal-
ing outputs, so synthekines could also exploit this parameter.
In addition to JAK2/JAK3 pairs, we observed other chimeric receptor pairs that did not appear to
activate signaling. We asked whether insertion of alanines in the juxtamembrane domain would
recover signaling by these receptors as well. Insertion of alanines in the juxtamembrane domains of
IL-2Rb, IL-12Rb, and EpoR did not recover signaling by the IL-2Rb-IL-2Rb, IL-12Rb-IL-23R and EpoR-
EpoR pairs (Figure 2—figure supplement 4). Strikingly, the IL-12Rb-IL-23R and EpoR-EpoR pairs
represent the receptor dimers engaged by IL-23 and EPO respectively. We think it is most likely that
the IL-1 receptor extracellular orientation and proximity is not favorable for some natural and non-
natural cytokine receptor pairs. This is a technical limitation of the chimeric receptor strategy we
used and we think that the lack of signaling for some of the pairs is not due to intrinsic inability for
particular JAK/TYK/STAT combinations to function, however this remains to be experimentally
tested. The collective results from the chimeric IL-1 receptor experiments is that many, if not most,
non-natural cytokine receptor pairs can signal through one or more STATs, but that certain pairs will
have distinct dimer orientation and proximity requirements that will depend on the synthekine.
Signal activation profiles induced by synthekines
We wished to explore whether dimerization of non-natural cytokine receptor pairs by synthekines
would activate signaling in unmodified cells (Figure 3A). We used a bi-specific strategy where we
fused two cytokines together, each of which could only bind to one of its two receptors, thus creat-
ing a defined 1:1 receptor dimer. To implement this approach, we engineered antagonist, or ‘domi-
nant negative (DN)’ versions of IL-4, IL-2, and IFN that preserve binding to their high affinity
receptor subunits (IL-4Ra for IL-4, IL-2Rb for IL-2, and IFNAR2 for IFN) but for which binding to their
low affinity receptor subunits has been disrupted (IL-13Ra1 and gc for IL-4, gc for IL-2, and IFNAR1
for IFN). These ‘DN’ cytokines function as high-affinity binding modules devoid of signaling activity
on their own. As anticipated, the wild type cytokines activated signaling in the Hut78 T cell line
(Figure 3B), but the dominant negative mutants were unable to promote signal activation, or at least
to nearly undetectable levels (Figure 3C). For the IL-2 cytokine, we used an engineered variant
denoted Super-2 that has 200-fold enhanced affinity for the IL-2Rb receptor subunit (Levin et al.,
2012) (Figure 3B). We then genetically fused pairs of dominant negative cytokine mutants with a
Gly4/Ser linker to generate new ligands that induce formation of IL-2Rb-IL-4Ra and IL-4Ra-IFNAR2
non-natural receptor dimers (Figure 3A).
When added to unmodified cell lines, these bi-specific-DN synthekines activated signaling profiles
that were qualitatively and quantitatively distinct from those induced by the parent cytokines
(Figure 3D). Stimulation of Hut78 cells with SY1 SL, which promotes dimerization of IFNAR2 and IL-
4Ra, resulted in STAT5 and STAT6 activation (Figure 3D). Notably, lengthening the polypeptide
linker connecting these two dominant negative proteins by 10 residues (SY1 LL) increased the signal-
ing potency exhibited by this synthekine (Figure 3D). Stimulation of Hut78 cells with SY2 synthekine,
Figure 2 continued
wheel projections of the register twists introduced by alanine residue addition are presented at right bottom. Each residue adds a 109˚ rotation, with
insertion of 3A residues bringing the register close to the original position. (C) Phospho-STAT3 (pSTAT3) and pSTAT5 levels measured by western blot
in IL-1-activated Jurkat cells expressing the indicated chimeric receptor pairs. Insertion of two alanines recovers signaling by the IL-1R1-EpoR/IL-
1R1AcP-gc receptor pair. Total levels of TYK2 are presented as a loading control. The western blot presented is a representative example of two
independent experiments.
DOI: 10.7554/eLife.22882.003
The following figure supplements are available for figure 2:
Figure supplement 1. Cell surface expression of chimeric receptors in Jurkat cells.
DOI: 10.7554/eLife.22882.004
Figure supplement 2. Signaling profiles activated by chimeric receptors in Jurkat cells.
DOI: 10.7554/eLife.22882.005
Figure supplement 3. Cell surface expression of EpoR chimeric receptors in Jurkat cells.
DOI: 10.7554/eLife.22882.006
Figure supplement 4. Alanine insertions do not recover signaling by the IL-23R-IL-12Rb, IL-2Rb-IL2Rb and EpoR-EpoR chimeric receptors.
DOI: 10.7554/eLife.22882.007
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Figure 3. Synthekines dimerizing non-natural cytokine receptor pairs activate signaling. (A) Layout and complex
formation by a synthekine. Two dominant negative cytokine variants are genetically fused by a Gly4/Ser linker,
resulting in a new molecule that induces formation of a non-natural cytokine receptor heterodimer. (B)-(D) pSTAT1,
pSTAT3, pSTAT5 and pSTAT6 levels activated by the IL-4, Super-2 (affinity-matured variant of IL-2), and IFNw
Figure 3 continued on next page
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which dimerizes IL-2Rb and IL-4Ra, resulted in STAT1 activation and weaker STAT3, STAT5 and
STAT6 activation (Figure 3D). In all instances, the synthekines elicited maximum responses (Emax)
significantly lower than those activated by genome-encoded cytokines. The different signaling pro-
grams activated by the synthekines do not appear to be the result of additive effects from the two
parental cytokines, as the signaling programs induced by adding pairs of parental cytokines simulta-
neously were dissimilar from those induced by the corresponding synthekines (Figure 3—figure sup-
plement 1).
In order to determine whether the signaling programs activated by the synthekines differed from
those activated by IL-2, IL-4 and IFN, we studied the activation of 120 different signaling molecules
by phospho-flow cytometry in the CD4+ T cell line Hut78 (Figure 4) (Moraga et al., 2015). Of the
120 molecules studied, twenty were activated by the ligands. The natural cytokine profiles were as
expected: Super-2 strongly activated STAT5 and the PI3K pathways (Figure 4A and B); IL-4 stimula-
tion robustly induced STAT6 and the PI3K pathway activation (Figure 4A and B); and IFN led to a
strong activation of all STATs molecules (Figure 4A and B). When Hut78 cells were stimulated with
the different synthekines, we could detect novel signaling programs engaged by these engineered
ligands. Stimulation with SY1 LL (herein referred to as SY1) strongly activated STAT5 and STAT6,
and also stimulated STAT1 and STAT3 to a lower extent (Figure 4A and B). In addition, this synthe-
kine induced strong activation of the PI3K pathway (i.e. GSK3B, Akt, RPS6) (Figure 4A). SY2 stimula-
tion resulted in an overall weaker signal than the other ligands, with preferential activation of STAT1
(Figure 4A and B). Moreover, the STAT activation ratios elicited by the cytokines and synthekines
differed significantly, with SY1 exhibiting a STAT5/STAT6 preference and SY2 exhibiting a STAT1
preference (Figure 4C). Principal component analysis of the signaling programs elicited by genome-
encoded cytokines and synthekines further confirm that synthekines activate distinct signaling pro-
grams and not only a subset of the original programs engaged by the parental cytokines (Figure 4—
figure supplement 1).
Cellular and signaling signatures induced by synthekines
We analyzed responses to synthekine treatment in 31 cell populations profiled from human PBMCs
via mass cytometry (CyTOF) (Bendall et al., 2011) (Figure 5A and Figure 5—figure supplement 1).
The native cytokines behaved as anticipated: Super-2 strongly activated STAT5, and also, to a lesser
extent, activated STAT1, STAT3, Erk, and S6R, exhibiting a clear T cell preference (Figure 5A); IL-4
stimulation resulted in potent activation of STAT6 and a homogenous signaling footprint for T cells
and monocytes, in agreement with the ubiquitous expression of the IL-4Ra and gc receptor subunits
(Figure 5A). Stimulation with IFN promoted strong activation of STAT5 and STAT6 and weaker acti-
vation of STAT1 and STAT3, in agreement with previous observations (van Boxel-Dezaire et al.,
2010) (Figure 5A). The IFN-induced STAT activation profile mapped into two different cell clusters,
with T cells inducing stronger STAT5 and STAT6 activation and B cells and monocytes exhibiting
strong STAT6 activation but weak STAT5 activation (Figure 5A). Cell signaling patterns elicited by
synthekines diverged from those elicited by endogenous cytokines (Figure 5A). The SY1 synthekine
induced strong STAT5 activation in T cells, but failed to activate signaling in NK, B cells, and mono-
cytes (Figure 5A). The SY2 synthekine elicited weak signal activation of each signal effector studied
in all cell populations, with a small bias towards STAT1 activation (Figure 5A).
Figure 3 continued
cytokines (B), the dominant negative cytokine variants IL-4DN, IL-2DN, and IFNDN (C), or the SY1 SL, SY1 LL, and
SY2 synthekines (D) in the Hut78 T cell, as measured by flow cytometry. Data (mean ± SD) are from two
independent replicates.
DOI: 10.7554/eLife.22882.008
The following figure supplement is available for figure 3:
Figure supplement 1. Signaling profiles activated by stimulation with Super-2/IL-4 and IL-4/IFN cytokine
combinations.
DOI: 10.7554/eLife.22882.009
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Figure 4. Synthekines activate different signaling programs than genome-encoded cytokines. (A) Bubble plot representation of the signaling pathways
activated by the indicated ligands after stimulation for 15, 60 or 120 min in Hut78 T cells. The size of the bubble represents the intensity of the signal
activated. (B) Filled radar representation of the signaling molecules activated by the genome-encoded cytokines and synthekines following 15 min
stimulation in Hut78 cells. The signaling molecules activated by the ligands are shown on the perimeter of the circle and their respective activation
Figure 4 continued on next page
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Cytokine secretion profiles induced by synthekines
After ligand stimulation, secreted cytokine levels in the extracellular milieu are often used to define
the nature of the immune response generated by a given cytokine (Zhu et al., 2010). We studied
the cytokine secretion signatures induced by synthekines versus native cytokines. PBMCs were stimu-
lated with IL-2, IL-4, IFN or the synthekines and the levels of 63 different analytes were measured
after 24 hr of stimulation via bead-based immunoassay (Figure 5B). Super-2 and the two synthekines
increased cytokine secretion, IFN had a neutral effect, and IL-4 reduced the amount of cytokine
secreted by PBMCs (Figure 5B). More detailed analysis of the data revealed that, as expected, stim-
ulation of PBMCs with Super-2 promoted secretion of high levels of LIF (Umemiya-Okada et al.,
1992), IL-13 (Hoshino et al., 1999) and IFNg (Kasahara et al., 1983) (Figure 5B). In addition, Super-
2 resulted in secretion of IL-22, and CD40L by PBMCs (Figure 5B). Also consistent with previous
reports, IFN stimulation induced secretion of IL-27 (Greenwell-Wild et al., 2009), while IL-4 stimula-
tion led to down-regulation of cytokines secreted by resting PBMCs, with IFNg being the most
potently down-regulated cytokine (Figure 5B) (Vercelli et al., 1990). Stimulation profiles for the two
synthekines differed from those induced by native cytokines. SY1 stimulation induced secretion of
many cytokines: IL-17F, IL-27, IL-13, IL17A, IFNg , BDNF, IL-23, FGFb, PDGFBB, and ENA78, and SY2
stimulation led to marginal levels of Eotaxin, BDNF and PDGFBB secretion (Figure 5B).
Synthekines dimerizing an RTK with a JAK/STAT receptor activate
signaling
JAK/STAT cytokine receptors represent only a subset of single-pass transmembrane receptors that
signal via dimerization-induced kinase activation. Receptor Tyrosine Kinases (RTKs) (e.g. EGFR [epi-
dermal growth factor receptor], c-Kit, etc), represent another large family of dimeric cell-surface
receptors that signal through trans-phosphorylation of their intracellular kinase domains
(Lemmon and Schlessinger, 2010). We wondered if we could extend the scope of synthekines to
include molecules that would compel heterodimerization and activation between a JAK/STAT cyto-
kine receptor and an RTK.
To assess the possibility of JAK/STAT receptor cross-talk with an RTK, we fused the TM and ICD
of EGFR to the ECD of IL-1R1 and transfected this construct together with our battery of IL-1R1AcP-
cytokine receptors ICDs in Jurkat cells (Figure 6A and B). All ten cytokine-receptor/EGFR pairs
expressed on the surface of Jurkat cells (Figure 6—figure supplement 1A). Stimulation with IL-1
resulted in variable degrees of phosphorylation of EGFR and, to a much lesser extent, STAT3 and
STAT5 proteins (Figure 6B), suggesting that these cytokine and tyrosine kinase receptors are, in
principle, capable of trans-phosphorylation when compelled through enforced proximity. This is con-
sistent with prior studies showing that examples exist of such cross-talk can occur on natural cells
(Vignais et al., 1996; Grant et al., 2002; Jahn et al., 2007; Wang et al., 2013). However, a caveat
to these chimeric receptor studies is that overexpression of kinase-linked receptors can lead to aber-
rant, artifactual phosphorylation events. Therefore we sought to enforce heterodimerization of JAK/
STAT and RTK-mediated receptors normally expressed on natural cells, in the absence of overex-
pression, using synthekine ligands.
We created a synthekine to compel dimerization of cKit, a tyrosine kinase receptor, and thrombo-
poietin receptor (TpoR), a JAK/STAT cytokine receptor. To design the synthekine bi-specific ligand,
we identified sequences of antibodies that bound with high affinity to either cKit andTpoR ECD,
Figure 4 continued
potencies are denoted by the radius of the circle. The different shapes of the filled radar exhibited by the different ligands define their distinct signaling
signatures. (C) Ratio of STAT activation by cytokines and synthekines after 15 min stimulation on Hut78 cells. Each column represents the total STAT
activation by each ligand normalized to 100%. The relative activation potency of each STAT is corrected accordingly. The different distribution of STAT
activation by the various ligands suggest differential STAT usages between genome-encoded cytokines and synthekines. Data (mean) are from two
independent replicates.
DOI: 10.7554/eLife.22882.010
The following figure supplement is available for figure 4:
Figure supplement 1. Unsupervised clustering of signaling programs engaged by cytokines and synthekines.
DOI: 10.7554/eLife.22882.011
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Figure 5. Synthekines elicit different cellular signatures and immune activities than genome-encoded cytokines. (A) Heat map representations of the
activation levels of six signal effectors induced by saturating doses of the indicated ligands in 29 immune cell types profiled from PBMCs, as measured
by mass cytometry (CyTOF). Data (mean) are from two independent replicates. (B) Detailed analysis of the secretion profiles of 63 cytokines from
Figure 5 continued on next page
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respectively. We reformatted each of them as single-chain variable fragments (scFvs), and enforced
their heterodimerization by fusing each with complementary acidic and basic leucine zippers
(Figure 6C), expressing and purifying them from insect cells, and applying them to the acute mega-
karyoblastic leukemia Mo7e cells, which are known to express cKit and TpoR. The SY4 and SY5 syn-
thekines both induced modest phosphorylation of cKit in Mo7e cells over background, but only SY5
induced detectable phosphorylation of TpoR-associated JAK2 over background, albeit very weakly
(Figure 6D). SY5 induced measurable Erk activation (50% Emax compared to the native ligand, stem
cell factor [SCF]) but only weak STAT5 activation, which is consistent with the apparent asymmetric
activation of cKit over TpoR (Figure 6E). Indeed, inhibition of JAK2 using a JAK2 small molecule
inhibitor resulted in loss of Erk activation by SY5, suggesting that the signaling program engaged by
these synthekines relies, at least in part, on JAK2 activity (Figure 6—figure supplement 1B). Thus,
there appears to be asymmetry in the efficiency of trans-phosphorylation within the TpoR/cKit
heterodimer.
We performed a high throughput phospho-flow cytometry-based study (Moraga et al., 2015) to
analyze the signaling response of 120 signaling molecules in stimulated Mo7e cells. As shown in
Figures 7A and 54 of the 120 different signaling molecules were activated above a significance
threshold by the different ligands. Interestingly the signaling signature elicited by SY5 appeared to
evoke qualitatively different outputs than SCF, TPO or the combination of the two ligands; depend-
ing on the pathway effector studied (Figure 7B and C). Collectively, the chimeric receptor and syn-
thekine studies show that, although inefficient compared to their natural ligands, JAK/TYK and RTK-
mediated signaling receptors are capable of cross-talk when compelled into heterodimeric com-
plexes by synthekines, which is consistent with prior studies suggesting that JAK and the RTK com-
ponents are capable of phosphorylating one another’s natural substrates (Vignais et al., 1996;
Grant et al., 2002; Jahn et al., 2007; Wang et al., 2013). More extensive exploration of this obser-
vation with optimized ligands tuned to maximize signaling output will be required to further clarify
this observation.
Discussion
In this study, we sought to expand the scope of kinase-linked dimeric receptor signaling on natural
cells using synthetic ligands, which we term Synthekines, to compel formation of non-natural recep-
tor dimers. Synthekines can be loosely analogized to ‘orphan’ cytokines since their physiological
functions are not known. However an important distinction from true orphan ligands is that synthe-
kines have known, pre-defined receptors, which greatly limits the potential functional scope of their
actions to the given cell types that express their receptors. This approach can exploit the full combi-
natorial potential of JAK/TYK/STAT, and RTK signaling through the creation of artificial receptor
dimers on natural cells. A compelling rationale for our exploring this approach is that, despite their
immunotherapeutic potential, relatively few cytokines are useful clinically, due in large part to their
pleiotropy and off-target effects (Andrews et al., 2006; Borden et al., 2007; Donohue and Rosen-
berg, 1983; Spangler et al., 2015). In recent years, cytokine variants have been engineered with
more defined activities and reduced toxicity (Juntilla et al., 2012; Levin et al., 2012, 2014). How-
ever, an intrinsic limitation to this approach is that engineered cytokines exhibit a subset of activities
within the bioactivity space occupied by the parental cytokine. Our proof-of-concept experiments
show that activation of distinct signaling programs and by extension, immune activities, can be
accomplished through engineering of synthetic cytokines (synthekines) that dimerize non-natural
cytokine receptor pairs. This approach offers the opportunity for generating ‘designer’ ligands to
specifically target biological processes relevant to health and disease.
Figure 5 continued
PBMCs stimulated with the indicated ligands. Cytokines that were secreted more than two fold above background are labeled. Data (mean ± SD) are
from two independent replicates.
DOI: 10.7554/eLife.22882.012
The following figure supplement is available for figure 5:
Figure supplement 1. Immune cell profiling to identify signaling signatures activated by cytokines versus synthekines.
DOI: 10.7554/eLife.22882.013
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Figure 6. Synthekines dimerizing a cytokine receptor and a tyrosine kinase receptor activate signaling. (A) Schematic representation of the IL-1-
mediated complexation of IL1-R1-EGFR and IL-1R1AcP-cytokine receptor chimeras. (B) Phospho-EGFR (pY EGFR), pSTAT3 and pSTAT5 levels measured
by western blot analysis in IL-1-activated Jurkat cells expressing the indicated chimeric receptor pairs. Total levels of Erk are presented as a loading
control. The western blot presented is a representative example of two independent experiments. (C) Layout and complex formation by a synthekine
Figure 6 continued on next page
Moraga et al. eLife 2017;6:e22882. DOI: 10.7554/eLife.22882 13 of 22
Research article Biophysics and Structural Biology Immunology
Our data show that synthekines activate distinct and novel signaling programs and induce secre-
tion of new cytokine signatures by stimulated PBMCs. However, we still lack a clear mechanistic
understanding for how specificity of synthekine signaling and activity is achieved. There are several
factors that could account for this specificity. First, while most synthekines elicit some signals that
partially resemble those of the parent cytokines, the ratio of activated STATs differs significantly
between the parent cytokines and synthekines. For instance, SY1 elicits a STAT6>STAT5>STAT1>-
STAT3 pattern instead of the STAT6>STAT1>STAT3>STAT5 pattern seen with IL-4 plus IFN, while
SY2 elicits a STAT1>STAT6>STAT5>STAT3 pattern instead of the STAT6>STAT5>STAT3>STAT1
pattern seen with IL-4 plus IL-2. The physiological relevance of different activated STAT ratios
remains to be fully understood; however several reports have shown that changes in STAT activation
ratios can alter cytokine-induced biological responses (Gil et al., 2012; Sharif et al., 2004;
Thomas et al., 2011). Second, given that synthekines induce dimerization of non-naturally occurring
cytokine receptor pairs, it is conceivable that they can change the abundance of STAT heterodimers
and possibly even induce formation of novel STAT heterodimer pairings, which could result in the
induction of completely novel gene expression programs and activities.
A limitation of our study is that we focused on human receptors and therefore have not carried
out in vivo experiments, but the results we present provide a compelling rationale for exploration of
synthekines in mouse systems and disease models. For investigation in mouse systems, suitable high
affinity binding modules to the receptor ECDs will need to be generated in order to create bi-spe-
cific entities. The physiological effects of synthekines will be no less complex than natural cytokines,
requiring in-depth study, but knowing the activities of the parent receptor chains used to form the
non-natural dimer could lend clues to potential new activities by the synthekine. For example, we
expect that in some cases the physiological effects and disease applications could be similar or
related to those of one of the parent receptor chains, while in other cases entirely distinct.
The synthekine design paradigm encompasses several critical considerations: (1) Selection of
two cytokine receptor subunits simultaneously expressed in the same cell. Cellular response to cyto-
kines is tightly regulated by surface expression patterns of cytokine receptor subunits (Levin et al.,
2012; Moraga et al., 2009; Wang et al., 2009). Thus, there are many cytokine receptor pair combi-
nations that, although compatible with signaling in principle, would not have physiological relevance
due to the lack of a naturally occurring cell subset that simultaneously expresses the two receptors
subunits. (2) Selection of the cytokine receptor subunit types to be dimerized by synthekines. From
our chimeric receptor study, we infer that most cytokine receptor pair combinations will activate sig-
naling to some extent. However, other parameters such as structural properties may influence the
degree and nature of signaling activation. For example, cytokine receptors can be subdivided into
two classes based on ICD length. Receptors with long ICDs often bind their ligands with high affinity,
pair with JAK1 or JAK2, encode for STAT binding sites, and drive signal activation (Murray, 2007;
Wang et al., 2009). In contrast, receptors with short ICDs often bind their ligands with lower affinity,
pair with TYK2 or JAK3, and minimally contribute to STAT recruitment and activation (Murray, 2007;
Wang et al., 2009). Interestingly, many receptor pairs that did not activate signaling in our chimeric
receptor study comprised short ICD receptors, suggesting that synthekines dimerizing two short
ICD receptor subunits would elicit weaker and less diverse signal activation programs than those
dimerizing long ICDs receptor subunits. In addition, our results show that synthekines dimerizing
Figure 6 continued
dimerizing a cytokine receptor and a tyrosine kinase receptor. Two scFvs binding a cytokine receptor and a tyrosine kinase receptor respectively are
genetically fused to acidic or basic leucine zippers, resulting in a new molecule able to form a heterodimeric receptor complex that does not exist in
nature. (D) Phospho cKit Y703 and pJAK2 levels measured by western blot in Mo7E cells after stimulation with synthekines that dimerize TpoR and cKit
(SY3, SY4 and SY5) for the indicated time periods. Total levels of Lamin are presented as a loading control. The western blot presented is a
representative example of two independent experiments. (E) Erk (left panel) and STAT5 (right panel) phosphorylation activated by 10 min stimulation
with the indicated doses of SCF, TPO, or the indicated synthekines in Mo7e cells, as measured by flow cytometry. Data (mean ± SD) are from three
independent replicates.
DOI: 10.7554/eLife.22882.014
The following figure supplement is available for figure 6:
Figure supplement 1. Functional characterization of tyrosine kinase receptor/cytokine receptor dimerizing synthekines.
DOI: 10.7554/eLife.22882.015
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Figure 7. Synthekines dimerizing a cytokine receptor and a tyrosine kinase receptor activate different signaling programs than their natural ligands.
(A) Bubble plot representation of the signaling pathways activated by the indicated ligands after stimulation for 10, 60 and 120 min in Mo7e cells. The
size of the bubble represents the intensity of the signal activated. (B) Stack column representation of the signaling molecules engaged by SCF, TPO
and SY5 after 10 min stimulation in Mo7e cells. For each molecule, the combined activation of the three ligands was normalized to 100% and the
Figure 7 continued on next page
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receptors from two different cell surface receptor families (specifically the cytokine receptor and the
tyrosine kinase receptor families) can activate signaling, albeit low efficiency, in accord with previous
findings that hinted at cross-talk between these receptor families (Wang et al., 2013).
An important aspect of the synthekine technology is that they dimerize cytokine receptor pairs in
a defined 1:1 molecular entity, which enables clear attribution of the signaling pathway to a specific
receptor dimer. Formation of a molecularly-defined surface complex by an engineered ligand is vital
for characterizing the signaling and phenotypic programs activated by these ligands. Previous
studies linked together two fully functional cytokines and generated ligands that could form multiple
independently functioning or mixed receptor complexes (Ng and Galipeau, 2015). In contrast, the
targeted synthekine approach using linked antagonist cytokine mutants or antibody-based binding
modules that can only bind to one receptor subunit, allows one to interrogate the activity of
specific receptor dimer pairs of defined composition and stoichiometry.
A consistent finding from our study was that the engineered synthekines were relatively inefficient
at activating signaling compared to the parent genome-encoded cytokines; at best we could detect
60% of the signaling amplitude induced by IL-2, IL-4, or IFN. The synthekines that evoked signaling
from the cKit/TpoR heterodimer exhibited even weaker activation properties. One possible explana-
tion for this observation is that the architecture of the cytokine-receptor complex appears to be a
determinant of signal potency (Moraga et al., 2015). It is thus possible that the receptor binding
topology induced by the engineered synthekines in both cases is suboptimal and that signaling
strength could be improved by altering the construction of these molecules in order to optimize the
receptor dimer topology. Future studies will focus on the identification of suitable molecular scaf-
folds that improve the efficiency of synthekine activation.
Materials and methods
Protein expression and purification
Human IL-4, Super-2, IFN, dominant negative cytokines, and synthekines were expressed and puri-
fied using a baculovirus expression system, as described in (Laporte et al., 2005). The sequence for
the Super-2 variant of IL-2 is provided in (Levin et al., 2012). The SY1 SL and LL synthekines were
generated by genetically fusing the IL-4DN and IFNDN proteins via a single (SY1 SL) or double (SY1
LL) Gly4Ser linker. The SY2 synthekine was generated by genetically fusing the IL-2DN and IL-4DN
proteins via a Gly4Ser linker. IL-4DN was generated by introducing the previously described R121D/
Y124D mutations on site II, which disrupt binding to common gamma chain (Wenzel et al., 2007).
IFNDN was generating by disrupting the binding to IFNAR1 by introducing the mutations F63A and
R120E on the IFNw-IFNAR1 binding interface. IL-2DN (also known as IL-2 RETR) was previously
described in Mitra et al. (2015). Single-chain variable fragments (scFvs) used for engineering SY3,
SY4 and SY5 were analogously expressed and purified in the baculovirus system via transfer of their
variable regions into the pAcGP67A vector (BD Biosciences, San Jose, CA) with an N-terminal gp67
signal peptide and a C-terminal hexahistidine tag. scFvs were expressed with the variable heavy (VH)
and variable light (VL) chains separated by a twelve-amino acid (Gly4Ser)3 linker fused either to acidic
or basic leucine zippers for dimerization. All proteins contained C-terminal hexahistidine tags and
were isolated by nickel chromatography and further purified to >98% homogeneity by size exclusion
chromatography on a Superdex 200 column (GE Healthcare, UK), equilibrated in 10 mM HEPES (pH
7.3) and 150 mM NaCl.
Figure 7 continued
relative contribution of each ligand was corrected accordingly. Some molecules were better activated by SCF, others were better activated by TPO, and
yet others were better activated by SY5. Data presented in panel A and B represents the mean value of two independent experiments performed in
triplicate. (C) pPLCG2, pErk, and pLCK levels induced by the indicated ligands in Mo7e cells after 10, 60 and 120 min stimulation. Data (mean ± SD) are
from three independent replicates.
DOI: 10.7554/eLife.22882.016
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Chimeric receptor generation
In order to generate the 10  10 signaling matrix, the ICDs of the 10 different parental cytokine
receptors were fused with the IL-1R1 and IL-1R1Acp ECDs. In the IL-1R1 ECD format, the nucleotide
sequence encoding the HA-tag was inserted between the end of the native signal sequence and the
first residue of the IL-1R1 ECD. Each ICD was fused to the 3’ end of IL-1R1 sequence. The IL-1R1Acp
chimeras were cloned in the same manner except the V5-tag was used. The boundaries of the
mature proteins and transmembrane spans were delineated using the SignalP (http://www.cbs.dtu.
dk/services/SignalP/) and TMHMM (http://www.cbs.dtu.dk/services/TMHMM/) webservers. The
DNA sequence used for IL-1R1 was codon optimized for expression in Homo sapiens as the organ-
ism (jcat.de) and synthesized (Integrated DNA Technologies). The chimeric receptors were cloned
into the pcDNA3.1 + vector (Invitrogen) using the NheI and KpnI restriction sites (NEB).
Receptor (ECD) Signal sequence Tag ECD start ECD end NCBI reference seq
IL-1R1 IL-1R1 HA 1 315 NM_000877.2
IL-1RAcp IL-1RAcp V5 1 335 NM_002182.3
Receptor (ICD) Cloning Start TM Start NCBI Reference Seq
EPO-R 223 226 NM_000121.3
gp130 595 598 BC117402.1
IFNAR1 408 411 NM_000629.2
IFNAR2 214 217 U29584.1
IL-12Rb 218 221 NM_005535.1
IL-13Ra1 219 222 NM_001560.2
IL-23R 218 221 NM_144701.2
IL-2Rb 215 218 NM_000878
IL-4Ra 218 221 NM_000418.3
gc 219 222 NM_000206.2
Tissue culture
Jurkat (CVCL_0367) and HUT78 (CVCL_0337) cell lines were acquired from the ATCC cell repository.
STR profiles were performed by ATCC to ensure identity of the lines. Mo7e (CVCL_2106) cells were
purchased from the DSMZ repository. Multiplex PCR of minisatellite markers performed by DSMZ
revealed a unique DNA profile. All cell lines were negative for mycoplasma. Jurkat cells were cul-
tured in DMEM complete medium (DMEM medium supplemented with 10% FBS, 2 mM L-glutamine,
and penicillin-streptomycin (Gibco, Waltham, MA)). Hut78 cells were cultured in RPMI complete
medium (RPMI 1640 medium supplemented with 10% FBS, 2 mM L-glutamine, and penicillin-strepto-
mycin (Gibco)). Mo7e cells were cultured in IMEM complete media (IMEM medium supplemented
with 10% FBS, 2 mM L-glutamine, 10 nM GM-SCF and penicillin-streptomycin (Gibco)). Prior to stim-
ulation, Mo7e cells were starved overnight in modified growth medium lacking FBS and GM-CSF. All
cell lines were maintained at 37˚C in a humidified atmosphere with 5% CO2.
Hut78 and Mo7e intracellular signaling studies
Approximately 3  105 Hut78 or Mo7e cells per well were placed in a 96-well plate, washed with
PBSA buffer (phosphate-buffered saline (PBS) pH 7.2, 1% BSA), and re-suspended in PBSA contain-
ing serial dilutions of the indicated ligands. Cells were stimulated for the prescribed time at 37˚C
and immediately fixed by addition of formaldehyde to 1.5% followed by incubation for 10 min at
room temperature. Cells were then permeabilized with 100% ice-cold methanol for 30 min at 4˚C.
The fixed and permeabilized cells were washed twice with PBSA and incubated with fluorescently-
labeled detection antibodies diluted in PBSA for 1 hr at room temperature. Fluorophore-
conjugated pSTAT3 (AB_647098), pSTAT5 (AB_11154412) and pSTAT6 (AB_399883) antibodies
were purchased from BD Biosciences (San Jose, CA). pSTAT1 (AB_10860764), pErk (AB_10695308),
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pcKit (AB_1147635), pEGFR (AB_331701) antibodies were purchased from Cell Signaling Technol-
ogy. Cells were then washed twice in PBSA buffer and mean fluorescence intensity (MFI) was quanti-
fied on an Accuri C6 flow cytometer. Dose-response curves were fitted to a logistic model and EC50
values were computed in the GraphPad Prism data analysis software after subtraction of the MFI of
unstimulated cells and normalization to the maximum signal intensity induced by wild-type cytokine
stimulation.
Peripheral blood mononuclear cell (PBMC) isolation from human whole
blood
Peripheral blood mononuclear cells (PBMCs) were isolated from human whole blood (Stanford Blood
Bank) using a gradient of Ficoll-Paque Plus (GE Healthcare) according to the manufacturer’s proto-
col. Freshly isolated PBMCs were used for both mass cytometry studies and bead-based immunoas-
says. Prior to stimulation, PBMCs were rested at 37˚C, 5% CO2 for 1 hr in RPMI complete medium.
Mass cytometry immune cell signaling analysis
This assay was performed in the Human Immune Monitoring Center at Stanford University. Freshly
isolated PBMC were seeded in 96-well plates at 5  105 cells per well and stimulated with serial dilu-
tions of the indicated ligands in RPMI complete for 20 min at 37˚C, 5% CO2. Cells were then fixed
via 10 min incubation in paraformaldehyde (1.5% final concentration) at room temperature. Cells
were washed and resuspended in CyFACS buffer (PBS supplemented with 2% BSA, 2 mM EDTA,
and 0.1% sodium azide) containing the metal-chelating polymer-labeled anti-surface antigen anti-
bodies for 30 min at room temperature. Antibodies were labeled from purified unconjugated, car-
rier-protein-free stocks from BD Biosciences, Biolegend (San Diego, CA), or Cell Signaling
Technology (Danvers, MA) and the polymer and metal isotopes were from DVS Sciences. Cells were
washed once in CyFACS buffer and then permeabilized overnight in methanol at  80˚C. The follow-
ing day, cells were washed once in CyFACS buffer and resuspended in CyFACS buffer containing
the metal-chelating polymer-labeled anti-intracellular antigen antibodies for 30 min at room temper-
ature. Cells were washed twice in PBS (phosphate-buffered saline pH 7.2), resuspended in iridium-
containing DNA intercalator (1:200 dilution in PBS, DVS Sciences) and incubated on ice for 20 min.
The cells were then washed three times in MilliQ water and then diluted in a total volume of 700 uL
in MilliQ water before injection into the CyTOF instrument (DVS Sciences, Sunnyvale, CA).
Data analysis was performed using FlowJo (CyTOF settings) by gating on cells based on the irid-
ium isotopes from the intercalator, then on intact singlets based on plots of one intercalator iridium
isotope vs. cell length, followed by cell subset-specific gating. Signal intensity for each condition is
reported as 90th percentile intensity minus that of an unstimulated control sample. Heat maps of the
response to the maximum concentration of each treatment were generated using the TM4 microar-
ray software suite (Dana-Farber Cancer Institute) (Saeed et al., 2003), with signal intensities normal-
ized to the maximum signal effector response in each cell type. Two independent replicates of mass
cytometry experiments were performed with similar results obtained.
Bead-based immunoassay cytokine secretion studies
This assay was performed in the Human Immune Monitoring Center at Stanford University. Freshly
isolated PBMCs (1.5  105 per well) were stimulated with the indicated ligands in the presence of 1
mg/mL phytohaemagglutinin (PHA) in RPMI complete and incubated for 24 hr at 37˚C, 5% CO2. Cells
were then pelleted via centrifugation and supernatants were harvested for bead-based immunoassay
analysis using the Luminex platform (Luminex Corporation, Austin, TX). Human 63-plex kits were pur-
chased from eBiosciences/Affymetrix and used according to the manufacturer’s recommendations
with modifications as described below. Briefly: Beads were added to a 96 well plate and washed in a
Biotek ELx405 washer. Harvested supernatants were added to the plate containing the mixed anti-
body-linked beads and incubated at room temperature for 1 hr followed by overnight incubation at
4˚C with shaking. Cold and room temperature incubation steps were performed on an orbital shaker
at 500–600 rpm. Following the overnight incubation, plates were washed in a Biotek ELx405 washer
and biotinylated detection antibody was added for 75 min at room temperature with shaking. Plates
were washed again as above and streptavidin-PE (Invitrogen, Waltham, MA) was added. After incu-
bation for 30 min at room temperature, a final wash was performed as above and reading buffer was
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added to the wells. Plates were analyzed on a Luminex 200 instrument with a lower bound of 50
beads per sample per cytokine. Custom assay Control beads (Radix Biosolutions, Georgetown, TX)
were added to all wells. Each sample was measured in duplicate and raw MFI was averaged from
the two replicates. Results are presented as fold change in MFI of treated cells relative to control
cells stimulated with PHA only.
Primity bio pathway phenotyping
Hut78 or Mo7e cells were stimulated with saturating concentrations of the indicated ligands for 15,
60 and 120 min and fixed with 1% PFA for 10 min at room temp. The fixed cells were prepared for
antibody staining according to standard protocols (Krutzik and Nolan, 2003). Briefly, the fixed cells
were permeabilized in 90% methanol for 15 min. The cells were then stained with a panel of antibod-
ies specific to the markers indicated (Primity Bio Pathway Phenotyping service) and analyzed on an
LSRII flow cytometer (BD Biosciences). The log2 ratio of the MFI of the stimulated samples divided
by the unstimulated control samples were calculated as a measure of response.
Western blot analysis
Cells were lysed in 1% NP-40 lysis buffer and 30 mg protein was analyzed as described in
(Marijanovic et al., 2007). The following polyclonal antibodies were used: anti-phospho Tyk2, anti-
phospho STAT1; anti-phospho STAT2; anti-phospho STAT3; anti-phospho STAT4; anti-phospho
STAT5; anti-phospho STAT6; anti-phospho EGFR; anti-phospho cKit pY703 (Cell Signaling Technol-
ogy). Signal was revealed with the ECL enhanced chemiluminescence Western blotting reagent
Western Lightning Chemiluminescence Reagent Plus (PerkinElmer, Waltham, MA).
Electroporation
15–20  106 Jurkat cells maintained at densities between 0.5–1.0  106 cells/ml were washed twice
with RPMI medium (sterile) and resuspended in 0.25 ml of Ingenio electroporation solution (Mirus-
bio, Madison, WI). 5–30 ug DNA (not exceeding 15% of the total volume) was added to the resus-
pended Jurkat cells and the mixture was transferred to a 4 mm gap cuvette (Invitrogen) and
incubated for 15–20 min room temperature. Cells were electroporated in a Biorad (Hercules, CA)
electroporator set at 0.28 kV and 960 mF. After electroporation, cells were transferred to pre-
warmed media (without Pen/Strep) and cultured normally. Protein expression was monitored after
24 hr.
Cell surface receptor staining
Surface receptor levels were monitored as described in (Marijanovic et al., 2007), using fluores-
cently-labeled monoclonal antibodies specific for the HA and V5 tags (Cell Signaling Technology).
Electroporated Jurkat cells were resuspended in cold PBS containing 3% fetal calf serum and incu-
bated with the indicated antibodies for 1 hr. Samples were analyzed on an Accuri C6 flow cytometer
(BD Biosciences).
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